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Abstract  Fecal  immunochemical  test  (FIT)  is  a  screening  tool  for  detecting  neoplastic  lesions
in asymptomatic  patients.  Colonoscopy  is  indicated  in  levels  of  FIT  >100  ngHb/ml.
Aim: Compare  the  frequency  of  advanced  adenomas  (AA)  in  colonoscopy  between  asymptomatic
subjects with  FIT+  vs.  symptomatic  patients.  Evaluate  the  level  of  bleeding  of  AA.
Material and  methodology: Cross-sectional,  observational  study  of  2829  consecutive  patientes
referred  for  colonoscopy.  We  collected  clinic-demographic  information,  AA  (size,  topography,
and histology)  and  FIT  quantiﬁcation.  We  included  2829  subjects  who  underwent  colonoscopy.
Statistics:  2,  Student’s  t-tests  (0.05),  one-way  ANOVA  and  ANCOVA  were  performed  for
adjusted contrasts  among  lesions,  gender,  positive  left  colonic  ﬁndings  and  age.
Results:  Global  rate  of  AA  was  7.2%.  Detection  of  AA  was  higher  in  average-risk  asymptomatic
subjects  than  in  symptomatic  (8.9  vs.  4.35%);  no  differences  in  age,  sex  or  site  of  lesion  was
ﬁnd. Group  1:  (n  =  902).  105  AA  (alone:  80.2%;  ≤9  mm:  27.2%;  10--15  mm:  62.9%  and  ≥16  mm:
 patients  (females:  38.2%;  mean  age:  64.1  ±  8.4  years).  Group  2:
1%)  in  symptomatic  patients.9.9%) were  detected  in  81
(n =  1927).  AA  105  in  84  (5.∗ Corresponding author at: Digestive Cancer Center, National Cancer Institute, Joanicó 3265, Montevideo, CP 11600, Uruguay.
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Quantitative  FIT  showed  a  correlation  between  AA  size  and  bleeding  level.  For  each  mm  that
increased the  size  of  the  AA,  the  bleeding  level  increased  35  ±  9  ngHb  with  a  stop  limit  of  15  mm.
Conclusions:  Detection  was  higher  in  average-risk  asymptomatic  subjects  with  FIT+  than  in
symptomatic  patients.  Quantitative  FIT  showed  a  correlation  between  adenoma  size  and  bleed-
ing level.
©  2014  Asociación  Mexicana  de  Endoscopia  Gastrointestinal.  Published  by  Masson  Doyma  México
S.A. This  is  an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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Heces
Utilidad  de  la  prueba  inmunoquimica  de  sangre  oculta  en  heces  para  la  deteccion  de
adenomas  avanzados  en  poblacion  de  riesgo  promedio  para  cancer  colorectal
Resumen  La  Prueba  Inmunoquímica  (FIT)  es  una  herramienta  de  tamizaje  para  detectar  sangre
oculta en  heces  en  sujetos  asintomáticos.  Pacientes  con  prueba  positiva  (≥100  ngHb/ml)  son
referidos  para  colonoscopía.
Objetivo:  Comparar  la  frecuencia  de  Adenomas  Avanzados  (AA)  detectados  en  colonoscopía
entre sujetos  asintomáticos  FIT+  vs.  pacientes  sintomáticos.  Determinar  el  nivel  de  sangrado
de los  AA.
Materiales  y  métodos:  Estudio  observacional  con  análisis  transversal  en  2,829  pacientes  con-
secutivos enviados  a  colonoscopía.  Se  tomaron  datos  clínico-demográﬁcos,  edad,  sexo,
presencia  de  adenoma  avanzado  (taman˜o,  topografía,  e  histología)  y  valor  del  FIT.  Incluimos
sujetos  con  colonoscopia  (902  FIT+  y  1,927  sujetos  sintomáticos).
Estadística:  Pruebas  X2,  t  de  student  (0.05),  ANOVA  y  ANCOVA  para  ajustar  contraste  entre
lesiones, sexo,  hallazgos  en  colon  izquierdo  y  edad.
Resultados:  Frecuencia  global  de  AA,  7.2%.  Fue  mayor  en  asintomáticos  (riesgo  promedio)  (8.9
vs. 4.35%)  que  en  sintomáticos,  sin  diferencias  en  edad,  sexo  o  sitio  de  la  lesión.  Grupo  1:
(n=902); 105  AA  (únicos:  80.2%:  ≤9  mm,  27.2%:  10--15  mm:  62.9%  y  ≥16  mm:  9.9%)  en  81  sujetos
(mujeres:  38.2%;  edad:  64.1  ±  8.4  an˜os).
Grupo  2:  (n=1,927),  AA  105  en  84  (5.1%)  pacientes  sintomáticos.
La cuantiﬁcación  del  FIT  mostró  relación  entre  el  taman˜o  del  AA  y  el  nivel  de  microsangrado.
Por cada  mm  que  aumenta  el  taman˜o  del  AA,  el  microsangrado  aumenta  35  ±  9  ngHb,  pero  el
valor del  FIT  deja  de  incrementarse  en  los  15  mm.
Conclusiones:  La  detección  de  AA  fue  mayor  en  pacientes  asintomáticos  con  riesgo  promedio
y FIT+.  La  prueba  mostró  relación  proporcional  entre  el  taman˜o  del  AA  y  la  magnitud  de  la
microhemorragia.
© 2014  Asociación  Mexicana  de  Endoscopia  Gastrointestinal.  Publicado  por  Masson  Doyma  Méx-
ico S.A.  Este  es  un  artículo  Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
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the  Digestive  Cancer  Center  (DCC),  we  use  immunochemi-Introduction
Colorectal  cancer  (CRC)  mainly  affects  the  economically
active  population  and  is  the  most  frequent  digestive  neo-
plasms.  One  element  of  great  importance  in  prevention
and  timely  detection  programs  is  the  increase  in  the  inci-
dence  of  CRC  in  subjects  aged  between  45  and  50  years.1,2
The  primary  objective  of  the  screening  was  to  detect  CRC
in  asymptomatic  subjects.1 The  precancerous  phase  (ade-
noma)  is  asymptomatic;  presents  in  up  to  90%  of  cases  and  is
due  to  a  non-linear  accumulation,  scaled,  number  of  genetic
alterations  and  chromosomal  alterations,  which  occur  during
the  time  course  of  approximately  7--10  years.3
Advanced  adenoma  (AA)  is  deﬁned  as  an  adenoma  with
one  of  the  following  items:  size  >10  mm,  villous  compo-
nent  >25%  and/or  High-grade  dysplasia  (HGD)4,5;  these  have
a  greater  risk  of  malignization  (50%);  thus,  they  must  be
c
(
Aesected.  The  risk  increases  in  synchronous  AA,  mainly  in
he  elderly.4 After  resection,  the  patient  should  begin  a
olonoscopic  surveillance  program  to  detect  metachronous
denomas  prior  to  their  malignant  transformation.6
Surveillance  programs  (the  National  Polyp  Study)  recom-
end  colonoscopy  3  years  after  the  resection  of  an  AA,
ecause  there  is  a  3.3%  rate  of  detection  of  new  polyps.7,8
denomas  can  be  detected  in  the  colonoscopy  through
creening  or  by  reference  symptoms  (digestive  bleeding).  A
haracteristic  of  early  CRC  and  most  of  the  Advanced  Ade-
oma  is  the  occult  bleed;  tests  that  detected  this  bleeding
llowed  the  early  diagnosis  of  these  lesions.9
In  the  Early  Prevention  and  Detection  of  CRC  Program  atal  test  to  detect  occult  blood  in  feces  (FIT  --  OC  Hemodia
Eiken  Chemical  Co.,  Tokyo,  Japan))  as  a  tool  for  screening.
 positive  test  (≥100  ngHb/ml)  suggests  a  high  probability
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ferences  were  observed  in  analysis  by  age,  gender,  or  lesion
site.
Table  1  Relationship  between  age  and  adenoma  size.
Adenoma  size
≤9  mm  10--15  mm  ≥16  mm
Average  age  (years)  65.5  (8.2)  63.6  (8.8)  63.1  (8.8)
Table  2  Number  of  endoscopic  and  histological  character-
istics  of  AA.
Adenoma  size
≤9  mm  10--15  mm  ≥16  mm
AA  characteristics 1.09  (0.4)  1.44  (0.6)  2.5  (0.7)
Table  3  Relation  between  bleeding  levels  (FIT  average)
and AA  size.
Adenoma  size6  
f  occult  bleeding  or  microbleeding  associated  with  benign
r  malignant  lesions;  thus,  the  patient  should  be  referred
or  colonoscopy  (screening).10--15
The  objective  of  the  study  was  to  compare  the  colono-
copic  detection  rate  of  AA  in  asymptomatic  subjects
average  risk)  with  a  positive  FIT  test  vs.  symptomatic  sub-
ects.  A  secondary  objective  was  to  evaluate  the  usefulness
f  quantiﬁcation  FIT  in  the  correlation  between  adenoma
ize  and  bleeding.
aterials and methods
e  conducted  an  observational,  comparative  study  with
ransversal  analysis  of  a  series  of  consecutive  cases  of
symptomatic  subjects  with  average  risk  (FIT-positive)  and
atients  with  colonic  symptoms  submitted  to  program
olonoscopy  at  the  CDC  of  the  National  Cancer  Institute  of
ontevideo,  Uruguay.  In  the  2829  colonoscopies  performed,
05  (7.2%)  lesions  were  found  with  endoscopic  and/or  his-
ological  criteria  of  advanced  adenoma:
Group  1:  Asymptomatic  subjects  with  average  risk  with
ositive  FIT  (n  =  902),  and  Group  2:  symptomatic  patients
n  =  1927).
Data  were  captured  in  a  Lotus  Approach  version  9.7  for
indows  database  and  included  age,  gender,  topography,
ize,  histopathological  diagnosis  and  quantiﬁcation  of  FIT.
e  also  considered  patients  with  two  or  more  advanced  ade-
omas;  in  these  cases,  we  analyzed  the  largest-sized  lesion
r  that  localized  nearest  the  cecum.
perational description of the variables
ubjects  at  average  risk  for  CRC:  Asymptomatic  subjects
ged  >50  years,  without  antecedents  of  CRC  of  adenomas.2--4
Advanced  adenomas: Adenomas  >10  mm  or  villous  com-
onent  >25%  or  high-grade  dysplasia  (HGD).3,4
Fecal  immunochemical  test: A  screening  tool  for  inves-
igating  occult  blood  in  fecal  matter  by  means  of  an
mmunochemical  test  (Fecal  Immunochemical  Test  --  OC-
iken  [Eiken  Chemical  Co.,  Eiken,  Japan])  (FIT),  which  is
 human  antihemoglobin  antibody  based  on  a  reaction  of
atex  agglutination  that  possesses  the  advantages  of  high
ensitivity,  which  does  not  activate  with  animal  hemoglobin
or  with  peroxidase  of  plant  origin;  thus,  it  does  not  require
 special  diet  and  is  easy  to  apply.8,9 Detect  bleeding  of  the
istal  ileum,  colon  and  rectum  and  do  not  have  interfer-
nce  with  the  intake  of  NSAIDs.  The  test  has  high  speciﬁcity
96--98%)  and  sensitivity  (91--95%),  and  is  a  qualitative  and
uantitative  method  because  automatic  processing  allows
etermination  of  the  level  of  hemoglobin  contained  in  the
tool.10,16 The  detection  range  is  from  0  to  2000  ngHb/ml
f  buffer,  which  allows  ﬁxing  the  cut-off  point  for  a  posi-
ive  result;  the  cut-off  point  at  our  Center  and  according
o  the  recommendation  of  the  manufacturers  was  set  at
00  ngHb/ml.9,13
Symptomatic  subjects:  Patients  with  different  colonic
ymptoms,  submitted  for  the  ﬁrst  colonoscopy.Statistical  analysis:  We  utilized  the  2 and  the  Fisher
xact  tests  for  categorical  variables  and  the  Student’s  t-
est  with  a  signiﬁcance  level  of  0.05  to  evaluate  differences
or  independent  samples.  We  employed  one-way  Analysis  ofE.  Fenocchi  et  al.
ariance  (ANOVA)  and  analysis  of  covariance  (ANCOVA)  to
djust  the  contrast  among  the  lesions  in  terms  of  gender,
ositive  colonic  ﬁndings,  and  age.  A  hyperbolic  function  was
alculated  for  two  parameters.  We  utilized  SPSS  version  17.0
or  Windows  and  Epi  Info  version  3.3.2.0  statistical  software.
esults
roup  1:  Eighty  one  of  902  (8.9%)  asymptomatic  subjects
ad  a  FIT+  (31  women;  average  age,  64.1  ±  8.4  years)  had
05  AA  (11.5%),  65  had  one  AA  (80.2%)  and  16  had  two  or
ore  AA  (19.8%).  Size  was  >10  mm  in  73.8%  of  cases  (22  AA,
9  mm;  51  AA,  10--15  mm,  and  8  AA,  ≥16  mm).  No  signiﬁcant
ifferences  were  observed  were  between  age  and  AA  size
Table  1).
Group  2:  Eighty  four  of  1927  (4.35%)  patients  with  symp-
oms  had  100  AA  (5.1%).
Considering  the  presence  of  one  of  more  characteris-
ics  of  AA  (HGD/≥25%  villous  component/size  ≥10  mm),  it
as  observed  that  those  smaller  in  size  presented  only  one
haracteristic,  and  those  of  a  larger  size,  >2  characteristics
Table  2).
Quantiﬁcation  of  the  bleeding  using  FIT  presented  a
irectly  proportional  relationship  with  the  size  of  the  ade-
oma  (Table  3)  with  a  15  mm  inﬂection  point,  at  which  the
alues  stopped  increasing,  becoming  a nearly  ﬂat  curve  of
etween  1100  and  1900  ngHb  (Fig.  1).
We  used  covariate  analysis  to  determine  the  association
etween  lesion  size  and  microbleeding  intensity,  adjusted
or  gender,  lesion  site  and  age.  The  parameters  show  that
or  each  mm  of  increase  in  size,  the  FIT  increased  the
emoglobin  value  in  35  ±  9  ng  (p  <  0.001).  No  signiﬁcant  dif-≤9  mm  10--15  mm  ≥16  mm
FIT  average  341.2  (278)  586.2  (471)  852.5  (411)
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of  patient  data.Figure  1  Correlation  between  AA  size  and  FIT  values.
Discussion
In  our  series,  the  global  frequency  of  advanced  adeno-
mas  detected  by  colonoscopy  was  7.2%.  The  detection  rate
was  higher  in  asymptomatic  subjects  with  a  positive  fecal
immunochemical  test  (FIT)  than  in  patients  with  symptoms
referred  for  colonoscopy  (8.9  vs.  4.3%).  Quantiﬁcation  of  the
bleeding  showed  a  directly  proportional  relationship  with
the  adenoma  size  and  a  15  mm  AA  size  inﬂection  point,  at
which  the  values  stopped  increasing,  becoming  a  nearly  ﬂat
curve  between  1100  and  1900  ngHb.
Negron  et  al.4 reported  a  global  frequency  of  9.6%  of  AA.
When  these  authors  analyzed  the  indication  for  colonoscopy
(symptomatic  or  FIT-positive),  they  observed  that  while  the
number  of  AA  detected  for  each  group  was  similar  (100/105
AA),  frequency  in  symptomatic  patients  (5.1%)  was  less  than
with  a  FIT+  (11.6%).  Our  study  reported  a  global  frequency
of  7.2%  of  advanced  adenomas,  with  8.9%  with  FIT  positive
and  4.3%  in  symptomatic  patients;  numbers  are  very  similar
to  those  of  the  previously  mentioned  authors.
The  frequency  of  synchronous  adenomas  was  of
30--50%  without  discriminating  whether  the  adenomas  were
advanced  or  not.8
In  our  series,  nearly  20%  had  a  synchronous  AA.  The  fre-
quency  of  metachronous  AA  and  a  recurrence  was  reported
as  9.37%  (range,  36--72  months)6 and  6.5%  at  4  years  in  the
postpolypectomy  follow-up.17
Early  detection  programs  for  AA  exert  an  impact  on  the
reduction  of  the  incidence  of  cancer,  because  due  to  its
high  risk  of  malignant  transformation,  endoscopic  or  surgi-
cal  resection  interrupts  the  Adenoma--Cancer  sequence.15--18
Winaver19 suggested  evaluating  the  usefulness  of  screening
programs  by  means  of  AA  detection  rate,  nutritional  inter-
ventions  and  novel  chemoprevention  agents.  In  2006,  our
work  team  reported  a  global  diagnosis  of  AA  (1.24%)  in  the
10,573  patients  who  participated  in  the  Colorectal  Cancer
Prevention  and  Detection  Program15 and  a  detection  rate  of
14.9%  in  patients  with  a  positive  FIT  and  colonoscopy.
Usually,  the  objective  of  screening  in  subjects  with  aver-
age  risk  is  having  a  >95%  speciﬁcity  for  CRC.  This  is  obtained
with  a  cut-off  point  of  100  ngHb/ml  of  FIT.20Rozen  et  al.21 informed  ideal  cut-off  points  (Receiver
operating  characteristics,  [ROC])  for  detecting  CRC  or  AA
and  for  AA  alone  using  one,  two  or  three  tests.  The
R
o advanced  adenomas  67
reatest  Area  Under  the  Curve  (AUC)  was  reached  with  two
ests  for  detecting  CRC  (0.957;  95%  Conﬁdence  interval  [95%
I],  0.935--0.978;  p  =  0.67);  no  differences  were  found  with
he  AUC  between  the  number  of  tests  for  CRC  or  AA  and
A  alone.  The  positivity  rate  among  the  three  tests  was  not
igniﬁcantly  different  (Cochrane  test).
The  optimal  cut-off  point  has  an  economic  impact.  If
he  cut-off  point  is  determined  at  50  ngHb/ml,  sensitivity
ill  increase,  speciﬁcity  will  be  reduced,  but  additional
olonoscopies  will  be  necessary  and  many  persons  will
ave  irrelevant  ﬁndings  (false  positives).  When  the  cut-off
oint  is  increased  to  100  ngHb,  speciﬁcity  will  increase,
ith  the  need  for  fewer  colonoscopies,  but  there  will
e  the  risk  of  overlooking  malignant  lesions.22 That  is,
n  equilibrium  between  the  sensitivity  and  speciﬁcity  of
he  test  will  be  required  (ROC  curve)  to  achieve  greater
ost-effectiveness.
While  not  yet  demonstrated  to  date,  a  greater  risk  of
alignization  should  exist  in  AA  that  present  >1  of  the
ndoscopic  or  histological  characteristics  that  deﬁne  AA.
n  this  regard,  we  observed  that  nearly  all  adenomas  of
16  mm  in  size  had  a  villous  component  and/or  HGD.  Another
act  to  highlight  is  that  larger  lesions  size  had  higher
leeding.  Lesions  >16  mm  in  diameter  double  the  bleeding
agnitude  when  compared  with  those  <9  mm  in  diameter;
owever,  as  Table  1  shows,  all  lesions  >15  mm  had  signiﬁcant
leeding  values  and  these  values  were  similar,  indepen-
ently  of  the  size.  There  is  no  evidence  to  suggests  that
agnitude  of  the  bleeding  correlates  with  the  adenoma’s
opography.23
onclusions
n  our  series,  the  global  frequency  of  advanced  adenomas
etected  by  colonoscopy  was  7.2%.  The  high  rate  of  detec-
ion  justiﬁes  a  deeper  analysis  of  their  characteristics.  The
etection  rate  was  higher  in  asymptomatic  subjects  with
 positive  FIT  than  in  symptomatic  patients  referred  for
olonoscopy  (8.9  vs.  4.35%).  Bibliography  not  reported  the
elationship  between  bleeding  value  and  advanced  adenoma
ize;  in  our  study  the  FIT  increased  35  ±  9  ngHb/ml  for  each
m  of  increase  in  size  of  the  AA.  Quantiﬁcation  of  the  hem-
rrhage  showed  a  directly  proportional  relationship  with
denoma  size  with  a  15  mm  inﬂection  point,  at  which  values
top  increasing,  becoming  a  nearly  ﬂat  curve  between  1100
nd  1900  ng/Hb.
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